Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
But acquisition charges drag earnings into loss
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Subscribe To Our Newsletter & Stay Updated
